TY - JOUR
T1 - Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan
AU - Takesue, Yoshio
AU - Watanabe, Akira
AU - Hanaki, Hideaki
AU - Kusachi, Shinya
AU - Matsumoto, Tetsuro
AU - Iwamoto, Aikichi
AU - Totsuka, Kyoichi
AU - Sunakawa, Keisuke
AU - Yagisawa, Morimasa
AU - Sato, Junko
AU - Oguri, Toyoko
AU - Nakanishi, Kunio
AU - Sumiyama, Yoshinobu
AU - Kitagawa, Yuko
AU - Wakabayashi, Go
AU - Koyama, Isamu
AU - Yanaga, Katsuhiko
AU - Konishi, Toshiro
AU - Fukushima, Ryoji
AU - Seki, Shiko
AU - Imai, Shun
AU - Shintani, Tsunehiro
AU - Tsukada, Hiroki
AU - Tsukada, Kazuhiro
AU - Omura, Kenji
AU - Mikamo, Hiroshige
AU - Takeyama, Hiromitsu
AU - Kusunoki, Masato
AU - Kubo, Shoji
AU - Shimizu, Junzo
AU - Hirai, Toshihiro
AU - Ohge, Hiroki
AU - Kadowaki, Akio
AU - Okamoto, Kohji
AU - Yanagihara, Katsunori
N1 - Funding Information:
Conflict of interest Yoshio Takesue has received a speaker’s honorarium from Taisho Toyama Pharm. Co., Ltd, MSD Japan, Astellas Pharma Inc. and Pfizer Japan Inc. Akira Watanabe is a consultant to Daiichi-Sankyo Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Toyama Chemical Co., Ltd, and Otsuka Pharmaceutical Co., Ltd. A.W. has received a speaker’s honorarium from MSD Japan, Glaxo SmithKline K.K., Shionogi & Co. Ltd., Daiichi-Sankyo Co., Ltd, Taisho Toyama Pharmaceutical, Dainippon Sumitomo Pharma Co., Ltd, and Pfizer Japan Inc. and grant support from Astellas Pharma Inc., Kyorin Pharmaceutical Co., Ltd, Shionogi & Co. Ltd., Taisho Pharmaceutical Co., Ltd, Toyama Chemical Co., Ltd, Daiichi Sankyo Co., Ltd, Dainippon Sumitomo Pharma Co., Ltd, Taiho Pharma Co., Ltd, and Meiji Seika Pharma Co., Ltd. Shinya Kusachi has received a speaker’s honorarium from Shionogi & Co., Ltd, MSD Japan, and Taisho Toyama Pharmaceutical Co., Ltd. Keisuke Sunakawa received a research grant from Meiji Seika Pharma Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd. Yuko Kitagawa has received a speaker’s honorarium from Chugai Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, Shionogi & Co., Ltd, Coviden Japan Co., Ltd, and Ethicon Endo-Surgery, LLC. Y.K received a research grant from Chugai Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, and Yakult Honsha Co., Ltd.
PY - 2012/12
Y1 - 2012/12
N2 - To investigate the trends of antimicrobial resistance in pathogens isolated from surgical site infections (SSI), a Japanese surveillance committee conducted the first nationwide survey. Seven main organisms were collected from SSI at 27 medical centers in 2010 and were shipped to a central laboratory for antimicrobial susceptibility testing. A total of 702 isolates from 586 patients with SSI were included. Staphylococcus aureus (20.4 %) and Enterococcus faecalis (19.5 %) were the most common isolates, followed by Pseudomonas aeruginosa (15.4 %) and Bacteroides fragilis group (15.4 %). Methicillin-resistant S. aureus among S. aureus was 72.0 %. Vancomycin MIC 2 μg/ml strains accounted for 9.7 %. In Escherichia coli, 11 of 95 strains produced extended-spectrum β-lactamase (Klebsiella pneumoniae, 0/53 strains). Of E. coli strains, 8.4 % were resistant to ceftazidime (CAZ) and 26.3 % to ciprofloxacin (CPFX). No P. aeruginosa strains produced metallo-β-lactamase. In P. aeruginosa, the resistance rates were 7.4 % to tazobactam/piperacillin (TAZ/PIPC), 10.2 % to imipenem (IPM), 2.8 % to meropenem, cefepime, and CPFX, and 0 % to gentamicin. In the B. fragilis group, the rates were 28.6 % to clindamycin, 5.7 % to cefmetazole, 2.9 % to TAZ/PIPC and IPM, and 0 % to metronidazole (Bacteroides thetaiotaomicron; 59.1, 36.4, 0, 0, 0 %). MIC90 of P. aeruginosa isolated 15 days or later after surgery rose in TAZ/PIPC, CAZ, IPM, and CPFX. In patients with American Society of Anesthesiologists (ASA) score ≥3, the resistance rates of P. aeruginosa to TAZ/PIPC and CAZ were higher than in patients with ASA ≤2. The data obtained in this study revealed the trend of the spread of resistance among common species that cause SSI. Timing of isolation from surgery and the patient's physical status affected the selection of resistant organisms.
AB - To investigate the trends of antimicrobial resistance in pathogens isolated from surgical site infections (SSI), a Japanese surveillance committee conducted the first nationwide survey. Seven main organisms were collected from SSI at 27 medical centers in 2010 and were shipped to a central laboratory for antimicrobial susceptibility testing. A total of 702 isolates from 586 patients with SSI were included. Staphylococcus aureus (20.4 %) and Enterococcus faecalis (19.5 %) were the most common isolates, followed by Pseudomonas aeruginosa (15.4 %) and Bacteroides fragilis group (15.4 %). Methicillin-resistant S. aureus among S. aureus was 72.0 %. Vancomycin MIC 2 μg/ml strains accounted for 9.7 %. In Escherichia coli, 11 of 95 strains produced extended-spectrum β-lactamase (Klebsiella pneumoniae, 0/53 strains). Of E. coli strains, 8.4 % were resistant to ceftazidime (CAZ) and 26.3 % to ciprofloxacin (CPFX). No P. aeruginosa strains produced metallo-β-lactamase. In P. aeruginosa, the resistance rates were 7.4 % to tazobactam/piperacillin (TAZ/PIPC), 10.2 % to imipenem (IPM), 2.8 % to meropenem, cefepime, and CPFX, and 0 % to gentamicin. In the B. fragilis group, the rates were 28.6 % to clindamycin, 5.7 % to cefmetazole, 2.9 % to TAZ/PIPC and IPM, and 0 % to metronidazole (Bacteroides thetaiotaomicron; 59.1, 36.4, 0, 0, 0 %). MIC90 of P. aeruginosa isolated 15 days or later after surgery rose in TAZ/PIPC, CAZ, IPM, and CPFX. In patients with American Society of Anesthesiologists (ASA) score ≥3, the resistance rates of P. aeruginosa to TAZ/PIPC and CAZ were higher than in patients with ASA ≤2. The data obtained in this study revealed the trend of the spread of resistance among common species that cause SSI. Timing of isolation from surgery and the patient's physical status affected the selection of resistant organisms.
KW - Antibiotic susceptibility
KW - Bacteroides fragilis group
KW - Surgical site infections
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=84880443113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880443113&partnerID=8YFLogxK
U2 - 10.1007/s10156-012-0509-1
DO - 10.1007/s10156-012-0509-1
M3 - Article
C2 - 23143280
AN - SCOPUS:84880443113
SN - 1341-321X
VL - 18
SP - 816
EP - 826
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 6
ER -